Cushing's Syndrome

PostMI syndrome Dressler's syndrome

DubinJohnson Syndrome and Rotor's Syndrome

Behet's Syndrome

Hepatopulmonary Syndrome

US FDA panel to weigh efficacy, safety of Novartis Cushing's drug

On the same day last February California-based Corcept Therapeutics' Korlym (mifepristone), a cortisol receptor blocker, won approval by the US FDA as the first treatment in the US for patients with...

Corcept Begins Recovery After Disastrous Launch Of Korlym

By Brian L. Wilson:Last year, the drug developer Corcept Therapeutics (NASDAQ: CORT) received FDA approval for its flagship product Korlym (mifepristone) for the treatment of Cushing's syndrome.Invest...

FDA panel unanimously backs Novartis' pasireotide

FDA's Endocrinologic and Metabolic Drugs Advisory committee voted 10-0 that efficacy and safety data for pasireotide from Novartis AG (NYSE:NVS; SIX:NOVN) support approval to treat Cushing's disease....

Corcept trades GR-II antagonist royalties for non-dilutive cash from Pharmakon

Corcept Therapeutics has sold a total of $45 million worth of royalties for the recently launched Cushing's syndrome drug Korlym (mifepristone 300mg tablets) and any of its next-generation drugs in th...

Novartis’ Signifor Seeks Controlled-Data Edge In Cushing Market At Advisory Committee

Cushing’s disease treatment Signifor (pasireotide) underwent a randomized Phase III clinical trial, while the earlier approval of competitor Corcept Therapeutics’ Korlym (mifepristone) was based o...

Corcept raises $46.4 million

Corcept Therapeutics Inc. (NASDAQ:CORT) raised $46.4 million late Friday through the sale of 11 million shares at $4.22 in a follow-on underwritten by Credit Suisse. Corcept proposed the offering on J...

Corcept planning follow-on

Corcept Therapeutics Inc. (NASDAQ:CORT) proposed to sell 11 million shares in a follow-on underwritten by Credit Suisse. If sold at the Corcept's Friday close of $4.49, the company would raise $49.4 m...

Corcept in $30M royalty deal

Corcept Therapeutics Inc. (NASDAQ:CORT) granted a Pharmakon Advisors fund rights to receive up to $45 million in royalties on Corcept's products in exchange for $30 million in cash. In April, Corcept...

Mifepristone (Korlym) for cushing's syndrome.

Mifepristone: is there a place in the treatment of Cushing's disease?

The purpose was to review the use of mifepristone in the treatment of Cushing's syndrome (CS) in the context of other recently published studies. We review the use of mifepristone, as published in the...

High Prevalence of Normal Tests Assessing Hypercortisolism in Subjects with Mild and Episodic Cushing's Syndrome Suggests that the Paradigm for Diagnosis and Exclusion of Cushing's Syndrome Requires Multiple Testing.

Many Endocrinologists believe that a single determination of eucortisolism or a single demonstration of appropriate suppression to dexamethasone excluded Cushing's syndrome, except in what was previou...

The diagnosis of Cushing's syndrome.

Spontaneous Cushing's syndrome is well known but unusual clinical disorder. Many of the clinical features (central weight gain, glucose intolerance, hypertension, muscle weakness) are seen in other co...

Pros and cons of screening for occult Cushing syndrome.

Systematic screening studies performed mainly in patients with diabetes mellitus have revealed an unexpectedly high prevalence of occult Cushing syndrome. Such studies may provide a rationale for syst...